ZA986084B - CTL epitopes from EBV - Google Patents

CTL epitopes from EBV

Info

Publication number
ZA986084B
ZA986084B ZA986084A ZA986084A ZA986084B ZA 986084 B ZA986084 B ZA 986084B ZA 986084 A ZA986084 A ZA 986084A ZA 986084 A ZA986084 A ZA 986084A ZA 986084 B ZA986084 B ZA 986084B
Authority
ZA
South Africa
Prior art keywords
seq
ebv
cytotoxic
cell epitopes
present
Prior art date
Application number
ZA986084A
Other languages
English (en)
Inventor
Martina Alison Sherritt
Scott Renton Burrows
Rajiv Khanna
Original Assignee
Queensland Inst Med Res
Commw Scient Ind Res Org
Walter & Eliza Hall Inst Med
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queensland Inst Med Res, Commw Scient Ind Res Org, Walter & Eliza Hall Inst Med, Csl Ltd filed Critical Queensland Inst Med Res
Publication of ZA986084B publication Critical patent/ZA986084B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
ZA986084A 1997-07-10 1998-07-09 CTL epitopes from EBV ZA986084B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO7841A AUPO784197A0 (en) 1997-07-10 1997-07-10 Treatment of nasopharyngeal carcinoma

Publications (1)

Publication Number Publication Date
ZA986084B true ZA986084B (en) 1999-01-26

Family

ID=3802132

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA986084A ZA986084B (en) 1997-07-10 1998-07-09 CTL epitopes from EBV

Country Status (11)

Country Link
US (2) US6723695B1 (xx)
EP (1) EP1003773B1 (xx)
JP (1) JP2001509514A (xx)
CN (1) CN100526331C (xx)
AT (1) ATE418562T1 (xx)
AU (1) AUPO784197A0 (xx)
CA (1) CA2294732A1 (xx)
DE (1) DE69840383D1 (xx)
NZ (1) NZ501944A (xx)
WO (1) WO1999002550A1 (xx)
ZA (1) ZA986084B (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115786509A (zh) * 2022-10-21 2023-03-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种鼻咽癌患病风险预测试剂盒

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1233781A1 (en) 1999-11-24 2002-08-28 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
TW200416043A (en) * 2002-11-07 2004-09-01 Queensland Inst Med Res Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
EP1624890B1 (en) 2003-01-24 2011-07-13 University Of Massachusetts Medical Center Identification of vaccinia virus dominant t cell epitopes
US8067535B2 (en) 2003-01-24 2011-11-29 The University Of Massachusetts Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
FR2850384A1 (fr) * 2003-01-28 2004-07-30 Centre Nat Rech Scient Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives, et leurs applications
US8451808B2 (en) 2006-02-18 2013-05-28 Intel Corporation Techniques for 40 megahertz (MHz) channel switching
EP1826264A1 (en) * 2006-02-24 2007-08-29 Deutsches Primatenzentrum GmbH Primate model for orthopox virus infections
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
SG10201407519TA (en) * 2009-11-19 2015-01-29 Univ Singapore Method For Producing T Cell Receptor-Like Monoclonal Antibodies And Uses Thereof
EP2611905A4 (en) * 2010-09-01 2014-02-12 Baylor College Medicine EBV-SPECIFIC CYTOTOXIC T LYMPHOCYTES FOR THE TREATMENT OF LOCO-REGIONAL NASOPHARYNX CARCINOMA (NPC)
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
US10351824B2 (en) 2011-12-12 2019-07-16 Cell Medica Limited Process of expanding T cells
HRP20221303T1 (hr) 2012-02-09 2022-12-23 Baylor College Of Medicine SMJESE PEPTIDA ZA NASTAJANJE MULTIVIRUSNIH CITOTOKSIČNIH T-LIMFOCITA(CTLs) ŠIROKE SPECIFIČNOSTI
US10040827B2 (en) 2012-03-19 2018-08-07 Deutsches Krebsforschungszentrum B-cell receptor complex binding proteins containing T-cell epitopes
US9901632B2 (en) 2012-10-19 2018-02-27 The Council Of The Queensland Institute Of Medical Research Human herpesvirus immunotherapy
JP6659535B2 (ja) 2013-06-28 2020-03-04 オークランド ユニサービシーズ リミティド アミノ酸及びペプチド接合体及び接合方法
US10016494B2 (en) 2014-02-07 2018-07-10 Valorisation-Hsj, Limited Partnership Antigenic epitopes from EBV gp350/220 and uses thereof
EP3131575B1 (en) 2014-04-15 2024-05-08 Griffith University Group a streptococcus vaccine
BR112017009475B1 (pt) 2014-11-05 2021-10-05 Memorial Sloan Kettering Cancer Center Métodos de seleção de uma linhagem de células t e de um doador das mesmas, sistema de computador para selecionar uma linhagem de células t, meio legível por computador, uso de uma população de células t e método para a obtenção de uma linhagem de células t
JP2018505152A (ja) 2014-12-23 2018-02-22 アン ブリンブル マーガレット アミノ酸複合体及びペプチド複合体ならびにそれらの使用
CN107835690A (zh) * 2015-05-12 2018-03-23 纪念斯隆-凯特林癌症中心 通过t细胞疗法治疗埃巴病毒相关淋巴细胞增生性病症的方法
KR101794304B1 (ko) * 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 Ｅｂｖ 항원 특이 ｔ―세포 수용체 및 이의 용도
WO2017049291A1 (en) 2015-09-18 2017-03-23 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
DK3384052T3 (da) * 2015-12-04 2020-06-02 Agency Science Tech & Res Kliniske korrelater for immunterapieffekt
KR20180128915A (ko) 2016-02-26 2018-12-04 오클랜드 유니서비시즈 리미티드 아미노산 및 펩티드 접합체 및 접합 방법
SG11201809534UA (en) * 2016-05-25 2018-12-28 Council Queensland Inst Medical Res Methods of treating autoimmune disease using allogeneic t cells
ES2940418T3 (es) 2016-09-02 2023-05-08 Univ James Cook Péptido para la cicatrización de heridas
JP2019530449A (ja) 2016-09-23 2019-10-24 メモリアル スローン ケタリング キャンサー センター 幹細胞様メモリーｔ細胞の生成および養子免疫療法における使用
CN106397574A (zh) * 2016-10-21 2017-02-15 上海交通大学医学院附属新华医院 抗原表位肽及其应用
EP3538544B1 (en) 2016-11-09 2024-03-27 Griffith University Subtilase cytotoxin b subunit mutant
CN107267481A (zh) * 2017-05-09 2017-10-20 上海交通大学医学院附属新华医院 Cdk5抗原表位肽及其应用
AU2018355145A1 (en) 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
NL2023863B1 (en) 2019-09-20 2021-05-25 Univ Griffith Protein particles and uses thereof
CA3162559A1 (en) 2019-11-25 2021-06-03 Griffith University Immunogenic protein against gonococcal infection
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
CA3192632A1 (en) * 2020-10-07 2022-04-14 The Council Of The Queensland Institute Of Medical Research Herpesvirus polyepitope vaccines
EP4232076A1 (en) 2020-10-20 2023-08-30 The Chancellor, Masters and Scholars of The University of Oxford Methods and compositions for treating epstein barr virus-associated cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583564D1 (de) * 1984-08-23 1991-08-29 Hans Joachim Wolf Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
WO1993019092A1 (fr) 1992-03-19 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
AU1942595A (en) * 1994-03-16 1995-10-03 Csl Limited Cytotoxic t-cell epitopes
MY114769A (en) * 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
WO1996003144A1 (en) * 1994-07-27 1996-02-08 The Council Of The Queensland Institute Of Medical Research Polyepitope vaccines
AU3072395A (en) * 1994-07-27 1996-02-22 Csl Limited Polyepitope vaccines
GB9501300D0 (en) 1995-01-24 1995-03-15 Boughton Brian J Peptides which inhibit viruses
AU712364B2 (en) * 1996-05-24 1999-11-04 Council Of The Queensland Institute Of Medical Research, The EBV CTL epitopes
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115786509A (zh) * 2022-10-21 2023-03-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种鼻咽癌患病风险预测试剂盒

Also Published As

Publication number Publication date
EP1003773A4 (en) 2002-08-07
WO1999002550A8 (en) 2000-06-15
EP1003773A1 (en) 2000-05-31
DE69840383D1 (de) 2009-02-05
WO1999002550A1 (en) 1999-01-21
AUPO784197A0 (en) 1997-08-07
EP1003773B1 (en) 2008-12-24
CN100526331C (zh) 2009-08-12
ATE418562T1 (de) 2009-01-15
US6723695B1 (en) 2004-04-20
CN1269804A (zh) 2000-10-11
CA2294732A1 (en) 1999-01-21
JP2001509514A (ja) 2001-07-24
US20030152582A1 (en) 2003-08-14
NZ501944A (en) 2001-11-30

Similar Documents

Publication Publication Date Title
ZA986084B (en) CTL epitopes from EBV
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
NZ335612A (en) A composition containing cytotoxic specificT-cell epitopes being either Rev and/or Tat proteins from HIV virus for prevention and treatment of human immunodeficiency virus (HIV) infection
WO1999051748A3 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
FR12C0004I1 (xx)
AU3173297A (en) Exendin analogues, processes for their preparation and medicaments containing them
CY2612B2 (en) Compounds for immunotherapy and diagnosis of tuberculosis
CA2011878A1 (en) Immunogenic regions on the e7 protein of human papillomavirus type 16
EP0726758A4 (en) PEPTIDES FOR INDUCING A RESPONSE OF THE CYTOTOXIC T-LYMPHOCYTHES TARGETED AGAINST THE HEPATITIS B-VIRUS
GB2301591A (en) Cytotoxic T-cell epitopes
EP0687182A4 (en) PEPTIDES FOR INDUCING A RESPONSE OF THE CYTOTOXIC T-LYMPHOCYTES AGAINST THE HEPATITIS B VIRUS
EP0830456A4 (en) ISOLATED PROTEIN B NUCLEIC ACID MOLECULE REGULATED BY Fe (FrpB) AND VACCINE USING THE SAME
GB9825551D0 (en) EBV CTL Epitopes
EP0770624A3 (en) Peptide capable of inducing immune response to human gastric cancer and agent containing it for preventing or treating human gastric cancer
CA2064029A1 (en) Use of mycobacterium vaccae in the prevention of aids
CA2109977A1 (en) Giardia vaccines
WO1998039027A3 (en) Sialyl lewis antigens as targets for immunotherapy
EP1028754A4 (en) PREVENTION OF IMMUNE REACTIVITY DUE TO DEPTH OR INHIBITION OF ANTIGENT PRESENTING CELLS
ZA971403B (en) Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof.
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
SE9600436D0 (sv) Vaccine against hantavirus
AP2001002354A0 (en) Use of antibodies recognizing the interleukin-2 receptor in the prevention and /or treatment of infections by the AIDS viruses.
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
WO2000024876A3 (en) Spumavirus isolated from humans